PE-22-28 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
PE-22-28 is one of the most discussed peptides in the research community, with reports focusing on its effects on rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis. Superior TREK-1 inhibition (IC50: 0.12 nM vs 40-60 nM for native spadin) with rapid antidepressant effects in rodent stress models. 4-day onset compared to weeks for conventional antidepressants. No human clinical trials.
What Do Researchers Report About PE-22-28?
PE-22-28 (PE-22-28 (spadin analog, TREK-1 inhibitor)) is one of the most discussed Ion channel inhibitor peptide compounds in the peptide research community. Reports span effects on rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis.
Superior TREK-1 inhibition (IC50: 0.12 nM vs 40-60 nM for native spadin) with rapid antidepressant effects in rodent stress models. 4-day onset compared to weeks for conventional antidepressants. No human clinical trials.
What Are the Most Common Positive Reports?
Researchers frequently cite PE-22-28's effects on rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis as the primary benefits observed during standard cycles of 4-8 weeks.
Demonstrates antidepressant onset in 4 days versus 4-6 weeks for conventional medications — if human efficacy confirms, this would be the fastest-acting peptide antidepressant. This distinctive profile is a key reason PE-22-28 maintains its popularity despite the growing number of alternatives.
What Are the Common Criticisms?
The most common complaints about PE-22-28: Minimal toxicity in animal models. Potential hypertension from enhanced monoamine activity. Human safety unknown. GABAergic disruption possible.
Cost and sourcing quality are also frequent concerns — results vary significantly between vendors, which is why COA testing is essential.
How Does PE-22-28 Compare to Alternatives?
As a Ion channel inhibitor peptide, PE-22-28 competes with several similar compounds. Demonstrates antidepressant onset in 4 days versus 4-6 weeks for conventional medications — if human efficacy confirms, this would be the fastest-acting peptide antidepressant.
Could theoretically pair with SSRIs for enhanced antidepressant effects through complementary serotonergic mechanisms.
Bottom Line: Is PE-22-28 Worth It?
Based on the available research and community reports, PE-22-28 is considered promising for rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis. The key factors for success: consistent dosing (100-500 mcg daily once daily), quality sourcing, and realistic expectations over 4-8 weeks cycles.
Complete Guide
PE-22-28 : Benefits, Dosage, Side Effects & Research
Related Reading
- PE-22-28 Dosage Guide
- PE-22-28 Benefits
- PE-22-28 Side Effects
- PE-22-28 Stacking Guide
- PE-22-28 Cycle Guide
- PE-22-28 Research
Calculate Your PE-22-28 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for PE-22-28.
Open Calculator →Research-Grade Sourcing
If you're going to research PE-22-28, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is PE-22-28?
PE-22-28 (PE-22-28 (spadin analog, TREK-1 inhibitor)) is a Ion channel inhibitor peptide. Synthetic shortened analog of spadin with enhanced TREK-1 potassium channel specificity and brain stability. It is researched for rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis.
What is the recommended PE-22-28 dosage?
Common dosages: 100-500 mcg daily administered once daily via subcutaneous injection (proposed). Cycle length: 4-8 weeks. Half-life: 14-23 hours in rodents. Use our peptide calculator for exact reconstitution math.
What are the side effects of PE-22-28?
Minimal toxicity in animal models. Potential hypertension from enhanced monoamine activity. Human safety unknown. GABAergic disruption possible.
Is PE-22-28 safe?
PE-22-28 has shown a preliminary safety profile in research. Not FDA-approved. Investigational research peptide only. All research should follow appropriate safety protocols.